January 30, 2023Open Access

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

Key Points

Key points are not available for this paper at this time.

Abstract

MIRV demonstrated consistent clinically meaningful antitumor activity and favorable tolerability and safety in patients with FRα-high PROC who had received up to three prior therapies, including bevacizumab, representing an important advance for this biomarker-selected population.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Ursula A. Matulonis

Domenica Lorusso

Ana Oaknin

Journals

Journal of Clinical Oncology

Actions

Institutions

Dana-Farber Cancer Institute

Memorial Sloan Kettering Cancer Center

KU Leuven

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study